Prio Wealth Limited Partnership Lowers Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Prio Wealth Limited Partnership decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,573 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Prio Wealth Limited Partnership’s holdings in Bristol-Myers Squibb were worth $1,530,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Trilogy Capital Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.6% during the 3rd quarter. Trilogy Capital Inc. now owns 66,122 shares of the biopharmaceutical company’s stock valued at $3,421,000 after buying an additional 419 shares in the last quarter. Brown Lisle Cummings Inc. lifted its stake in shares of Bristol-Myers Squibb by 9.4% during the 3rd quarter. Brown Lisle Cummings Inc. now owns 23,315 shares of the biopharmaceutical company’s stock valued at $1,206,000 after buying an additional 2,002 shares in the last quarter. Vest Financial LLC purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at $438,000. Nepsis Inc. lifted its stake in shares of Bristol-Myers Squibb by 1,143.7% during the 3rd quarter. Nepsis Inc. now owns 70,768 shares of the biopharmaceutical company’s stock valued at $3,662,000 after buying an additional 65,078 shares in the last quarter. Finally, OLD National Bancorp IN increased its holdings in Bristol-Myers Squibb by 0.5% in the 3rd quarter. OLD National Bancorp IN now owns 206,914 shares of the biopharmaceutical company’s stock valued at $10,706,000 after acquiring an additional 1,113 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BMY. UBS Group lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. BMO Capital Markets reiterated a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. TD Cowen lifted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays lifted their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $53.20.

Bristol-Myers Squibb Trading Down 1.2 %

Shares of BMY stock traded down $0.63 during trading hours on Monday, reaching $52.59. 1,157,669 shares of the stock were exchanged, compared to its average volume of 14,685,340. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $56.77. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The company’s 50-day moving average price is $50.36 and its 200-day moving average price is $46.33. The firm has a market capitalization of $106.61 billion, a price-to-earnings ratio of -17.17, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. During the same period in the previous year, the company earned $1.75 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.